Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03425006
Title Pembrolizumab and Itacitinib (INCB039110) for NSCLC
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Pennsylvania
Indications

lung non-small cell carcinoma

Therapies

Itacitinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST